Overview

Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

Status:
Recruiting

Trial end date:
2022-01-17

Target enrollment:

Participant gender:

Summary

This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Instituto Brasileiro de Controle do Cancer

Treatments:

Olanzapine